vs
DLH Holdings Corp.（DLHC）与PUMA BIOTECHNOLOGY, INC.（PBYI）财务数据对比。点击上方公司名可切换其他公司
PUMA BIOTECHNOLOGY, INC.的季度营收约是DLH Holdings Corp.的1.1倍（$75.5M vs $68.9M），PUMA BIOTECHNOLOGY, INC.同比增速更快（27.7% vs -24.1%），PUMA BIOTECHNOLOGY, INC.自由现金流更多（$14.4M vs $-4.8M），过去两年PUMA BIOTECHNOLOGY, INC.的营收复合增速更高（31.3% vs -17.4%）
DLH Holdings Corp.是一家总部位于美国的政府服务供应商，主要为退伍军人事务部、国防部、卫生与公众服务部等联邦机构提供技术赋能的医疗、物流、工程及任务支持服务，同时服务部分州及地方公共部门客户。
彪马生物技术是一家公开上市的生物制药企业，总部位于美国加利福尼亚州洛杉矶，专注于创新药物研发相关业务，在生物制药领域开展研发与商业化运营。
DLHC vs PBYI — 直观对比
营收规模更大
PBYI
是对方的1.1倍
$68.9M
营收增速更快
PBYI
高出51.8%
-24.1%
自由现金流更多
PBYI
多$19.2M
$-4.8M
两年增速更快
PBYI
近两年复合增速
-17.4%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $68.9M | $75.5M |
| 净利润 | $-1.3M | — |
| 毛利率 | — | 69.3% |
| 营业利润率 | 2.1% | 22.7% |
| 净利率 | -1.9% | — |
| 营收同比 | -24.1% | 27.7% |
| 净利润同比 | -218.7% | — |
| 每股收益（稀释后） | $-0.09 | $0.26 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收DLHCPBYI
| Q4 25 | $68.9M | $75.5M | ||
| Q3 25 | $81.2M | $54.5M | ||
| Q2 25 | $83.3M | $52.4M | ||
| Q1 25 | $89.2M | $46.0M | ||
| Q4 24 | $90.8M | $59.1M | ||
| Q3 24 | $96.4M | $80.5M | ||
| Q2 24 | $100.7M | $47.1M | ||
| Q1 24 | $101.0M | $43.8M |
净利润DLHCPBYI
| Q4 25 | $-1.3M | — | ||
| Q3 25 | $-920.0K | $8.8M | ||
| Q2 25 | $289.0K | $5.9M | ||
| Q1 25 | $878.0K | $3.0M | ||
| Q4 24 | $1.1M | — | ||
| Q3 24 | $2.3M | $20.3M | ||
| Q2 24 | $1.1M | $-4.5M | ||
| Q1 24 | $1.8M | $-4.8M |
毛利率DLHCPBYI
| Q4 25 | — | 69.3% | ||
| Q3 25 | — | 77.7% | ||
| Q2 25 | — | 76.5% | ||
| Q1 25 | — | 77.1% | ||
| Q4 24 | — | 76.4% | ||
| Q3 24 | — | 63.9% | ||
| Q2 24 | — | 77.4% | ||
| Q1 24 | — | 75.5% |
营业利润率DLHCPBYI
| Q4 25 | 2.1% | 22.7% | ||
| Q3 25 | 2.8% | 17.6% | ||
| Q2 25 | 4.5% | 12.7% | ||
| Q1 25 | 5.7% | 8.7% | ||
| Q4 24 | 6.2% | 22.6% | ||
| Q3 24 | 6.6% | 27.4% | ||
| Q2 24 | 5.7% | -4.6% | ||
| Q1 24 | 5.9% | -5.3% |
净利率DLHCPBYI
| Q4 25 | -1.9% | — | ||
| Q3 25 | -1.1% | 16.2% | ||
| Q2 25 | 0.3% | 11.2% | ||
| Q1 25 | 1.0% | 6.5% | ||
| Q4 24 | 1.2% | — | ||
| Q3 24 | 2.4% | 25.2% | ||
| Q2 24 | 1.1% | -9.6% | ||
| Q1 24 | 1.8% | -11.0% |
每股收益（稀释后）DLHCPBYI
| Q4 25 | $-0.09 | $0.26 | ||
| Q3 25 | $-0.07 | $0.17 | ||
| Q2 25 | $0.02 | $0.12 | ||
| Q1 25 | $0.06 | $0.06 | ||
| Q4 24 | $0.08 | $0.40 | ||
| Q3 24 | $0.16 | $0.41 | ||
| Q2 24 | $0.08 | $-0.09 | ||
| Q1 24 | $0.12 | $-0.10 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $257.0K | $97.5M |
| 总债务越低越好 | $133.5M | $22.7M |
| 股东权益账面价值 | $112.2M | $130.3M |
| 总资产 | $283.5M | $216.3M |
| 负债/权益比越低杠杆越低 | 1.19× | 0.17× |
8季度趋势，按日历期对齐
现金及短期投资DLHCPBYI
| Q4 25 | $257.0K | $97.5M | ||
| Q3 25 | $125.0K | $94.4M | ||
| Q2 25 | $194.0K | $96.0M | ||
| Q1 25 | $196.0K | $93.2M | ||
| Q4 24 | $451.0K | $101.0M | ||
| Q3 24 | $342.0K | $96.7M | ||
| Q2 24 | $423.0K | $96.8M | ||
| Q1 24 | $238.0K | $107.2M |
总债务DLHCPBYI
| Q4 25 | $133.5M | $22.7M | ||
| Q3 25 | $128.0M | $34.0M | ||
| Q2 25 | $138.3M | $45.3M | ||
| Q1 25 | $147.3M | $56.7M | ||
| Q4 24 | $162.2M | $68.0M | ||
| Q3 24 | $149.4M | $79.3M | ||
| Q2 24 | $160.9M | $90.7M | ||
| Q1 24 | $164.8M | $102.0M |
股东权益DLHCPBYI
| Q4 25 | $112.2M | $130.3M | ||
| Q3 25 | $113.0M | $115.3M | ||
| Q2 25 | $113.7M | $104.7M | ||
| Q1 25 | $112.8M | $97.1M | ||
| Q4 24 | $111.4M | $92.1M | ||
| Q3 24 | $110.1M | $71.1M | ||
| Q2 24 | $108.6M | $48.5M | ||
| Q1 24 | $106.8M | $51.0M |
总资产DLHCPBYI
| Q4 25 | $283.5M | $216.3M | ||
| Q3 25 | $290.7M | $202.9M | ||
| Q2 25 | $299.3M | $194.9M | ||
| Q1 25 | $306.6M | $196.2M | ||
| Q4 24 | $325.0M | $213.3M | ||
| Q3 24 | $314.4M | $220.7M | ||
| Q2 24 | $325.0M | $205.0M | ||
| Q1 24 | $325.9M | $214.1M |
负债/权益比DLHCPBYI
| Q4 25 | 1.19× | 0.17× | ||
| Q3 25 | 1.13× | 0.30× | ||
| Q2 25 | 1.22× | 0.43× | ||
| Q1 25 | 1.31× | 0.58× | ||
| Q4 24 | 1.46× | 0.74× | ||
| Q3 24 | 1.36× | 1.12× | ||
| Q2 24 | 1.48× | 1.87× | ||
| Q1 24 | 1.54× | 2.00× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-4.8M | $14.4M |
| 自由现金流经营现金流 - 资本支出 | $-4.8M | $14.4M |
| 自由现金流率自由现金流/营收 | -7.0% | 19.1% |
| 资本支出强度资本支出/营收 | 0.1% | 0.0% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $29.2M | $41.7M |
8季度趋势，按日历期对齐
经营现金流DLHCPBYI
| Q4 25 | $-4.8M | $14.4M | ||
| Q3 25 | $10.7M | $9.7M | ||
| Q2 25 | $9.6M | $14.1M | ||
| Q1 25 | $14.5M | $3.6M | ||
| Q4 24 | $-11.5M | $15.6M | ||
| Q3 24 | $12.4M | $11.0M | ||
| Q2 24 | $4.6M | $1.0M | ||
| Q1 24 | $5.2M | $11.2M |
自由现金流DLHCPBYI
| Q4 25 | $-4.8M | $14.4M | ||
| Q3 25 | $10.7M | $9.7M | ||
| Q2 25 | $9.4M | $14.1M | ||
| Q1 25 | $14.0M | $3.6M | ||
| Q4 24 | $-12.1M | $15.6M | ||
| Q3 24 | $12.2M | $11.0M | ||
| Q2 24 | $4.5M | $1.0M | ||
| Q1 24 | $4.9M | — |
自由现金流率DLHCPBYI
| Q4 25 | -7.0% | 19.1% | ||
| Q3 25 | 13.1% | 17.7% | ||
| Q2 25 | 11.2% | 26.8% | ||
| Q1 25 | 15.6% | 7.7% | ||
| Q4 24 | -13.3% | 26.4% | ||
| Q3 24 | 12.7% | 13.7% | ||
| Q2 24 | 4.4% | 2.1% | ||
| Q1 24 | 4.9% | — |
资本支出强度DLHCPBYI
| Q4 25 | 0.1% | 0.0% | ||
| Q3 25 | 0.0% | 0.0% | ||
| Q2 25 | 0.3% | 0.0% | ||
| Q1 25 | 0.6% | 0.1% | ||
| Q4 24 | 0.6% | 0.0% | ||
| Q3 24 | 0.2% | 0.0% | ||
| Q2 24 | 0.2% | 0.0% | ||
| Q1 24 | 0.3% | 0.0% |
现金转化率DLHCPBYI
| Q4 25 | — | — | ||
| Q3 25 | — | 1.10× | ||
| Q2 25 | 33.12× | 2.41× | ||
| Q1 25 | 16.52× | 1.21× | ||
| Q4 24 | -10.35× | — | ||
| Q3 24 | 5.42× | 0.54× | ||
| Q2 24 | 4.06× | — | ||
| Q1 24 | 2.89× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
DLHC
| Sales Channel Directly To Consumer | $64.5M | 94% |
| Sales Channel Through Intermediary | $4.4M | 6% |
PBYI
暂无分部数据
